Our CTX therapy is a cell-based treatment for CLI patients, which, in pre-clinical studies, has shown the potential to restore sufficient blood flow in the affected lower limb to avoid amputation, and therefore the severe health consequences that typically result from such a procedure. The trial is being undertaken through NHS Tayside at Ninewells Hospital and Medical School, Dundee, Scotland. In this dose escalation safety study, the CTX cells will be administered via straightforward intramuscular injection into the affected lower limb of nine patients with peripheral arterial disease (CLI is the end-stage of this disease). Patients will be monitored for up to 12 months to assess the safety and tolerability of the treatment. Safety data is expected from this study in 2017.
Further information regarding our clinical trials, including relevant contact details, may be found on clinicaltrials.gov.